Effects of memantine and galantamine on cognitive performance in aged rhesus macaques.

Archive ouverte

Schneider, Jay S | Pioli, Elsa y | Jianzhong, Yang | Li, Qin | Bezard, Erwan

Edité par CCSD ; Elsevier -

International audience. Current pharmacotherapies for Alzheimer's disease (AD) are focused on improving performance of daily activities, personal care, and management of problematic behaviors. Both memantine, a noncompetitive N-methyl-D-aspartate channel blocker and galantamine, a selective acetylcholinesterase inhibitor, are currently prescribed as symptomatic therapies for AD. However, drugs that progressed directly from testing in rodent models to testing in AD patients in clinical trials failed to demonstrate consistent effects on cognitive symptoms. Considering the lack of nonhuman primate data on the effects of memantine and galantamine alone or in combination on cognitive dysfunction in aged nonhuman primates, the present study examined how closely data derived from aged nonhuman primates reflects data obtained in humans. Mild beneficial effects on aspects of cognitive performance in aged primates were found, in general agreement with the human clinical experience with these drugs but in contrast to the more positive effects reported in the rodent literature. These data suggest that the nonhuman primate might have more predictive validity for drug development in this area than comparable rodent assays.

Consulter en ligne

Suggestions

Du même auteur

Levodopa improves motor deficits but can further disrupt cognition in a macaque parkinson model

Archive ouverte | Schneider, Jay S. | CCSD

International audience. BACKGROUND:Levodopa effectively relieves motor symptoms in Parkinson's disease (PD), but has had inconsistent effects on cognition, even worsening some aspects of cognitive functioning. There...

An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models.

Archive ouverte | Ko, Wai Kin D | CCSD

International audience. Istradefylline (KW-6002), an adenosine A2A receptor antagonist, is used adjunct with optimal doses of L-3,4-dihydroxyphenylalanine (l-DOPA) to extend on-time in Parkinson's disease (PD) patie...

Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.

Archive ouverte | Bezard, Erwan | CCSD

International audience. The serotonin (5-hydroxytryptamine [5HT]) system has recently emerged as an important player in the appearance of l-3,4-dihydroxyphenylalanine (levodopa [l-dopa])-induced dyskinesia in animal...

Chargement des enrichissements...